Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal prednisolone
- Development stage
- Phase 2
- Lead developer
- Enceladus Pharmaceuticals
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Liposomal prednisolone is a novel intravenous formulation of the synthetic glucocorticoid corticosteroid prednisolone. In this formulation, the active drug is encapsulated within long-circulating (PEGylated) liposomes to enhance targeted delivery to inflamed tissues and reduce systemic exposure. This approach aims to improve the therapeutic index of glucocorticoids by increasing efficacy at sites of inflammation while minimizing adverse effects associated with systemic corticosteroid therapy. Liposomal prednisolone acts primarily as an agonist at the glucocorticoid receptor, inhibiting inflammatory pathways such as arachidonic acid metabolism and modulating immune responses. It has been investigated for use in rheumatoid arthritis (Phase III), arteriovenous fistula maturation (Phase II), Graves ophthalmopathy (Phase II), and ulcerative colitis (Phase II). Clinical studies suggest it may offer superior or comparable efficacy with potentially fewer side effects compared to conventional steroid regimens[2][4][5].
- Brand names
- Nanocort
- Other names
- liposome encapsulated prednisolonePEGylated liposomal prednisolonelong-circulating pegylated liposomal glucocorticoid
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on liposomal prednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal prednisolone.